TY - JOUR
AU - Damulin, I. V.
AB - Depression is a frequent complication of stroke and develops in about one third of survivors. It degrades the course of poststroke neurological impairments, increases the physical helplessness of patients, and decreases their quality of life, significantly reducing the efficacy of therapeutic and rehabilitation measures and increasing the risk of lethal outcomes. Antidepressants eliminate or decrease the symptoms of depression, promote reductions in neurological disorders, improve cognitive functions and patient’s overall status, increase the efficacy of treatment and rehabilitation, decrease the risk of repeat stroke, and decrease lethality. Preference in the treatment of poststroke depression is given to selective serotonin reuptake inhibitors; data have been obtained on the efficacy of other contemporary antidepressants, as well as tricyclic antidepressants. Unresolved aspects of this problem requiring further suitably designed controlled studies include the tolerance of antidepressants by elderly patients, selection of the appropriate drugs, and choice of treatment duration.
TI - Stroke and Depression
JF - Neuroscience and Behavioral Physiology
DO - 10.1007/s11055-020-00955-6
DA - 2020-07-02
UR - https://www.deepdyve.com/lp/springer-journals/stroke-and-depression-IKbHuFla5j
SP - 683
EP - 686
VL - 50
IS - 6
DP - DeepDyve
ER -